Wells Fargo’s Context Therapeutics CNTX Stock Holding History

Wells Fargo’s Portfolio CNTX Stock Details CNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-116	Closed	-$160	–	6993
2024 Q1	$160	Buy	116 +2	+2%	+$2	﹤0.01%	6547
2023 Q4	$129	Buy	114 +6	+6%	+$6	﹤0.01%	6706
2023 Q3	$163	Buy	108 +1	+0.9%	+$1	﹤0.01%	6634
2023 Q2	$171	Buy	107 +4	+4%	+$3	﹤0.01%	6744
2023 Q1	$58	Buy	103 +2	+2%	+$2	﹤0.01%	7068
2022 Q4	$66	Buy	101 +2	+2%	+$2	﹤0.01%	6916
2022 Q3	$0	Buy	99 +30	+43%	+$54	﹤0.01%	6733
2022 Q2	$0	Buy	69 +5	+8%	+$9	﹤0.01%	6873
2022 Q1	$0	Buy	64 +31	+94%	+$65	﹤0.01%	7138
2021 Q4	$0	Buy	+33	New	+$165	﹤0.01%	7275

Other funds holding CNTX

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

Wells Fargo's CNTX Position: Q2 2024 in Review

Wells Fargo sold out of Context Therapeutics (CNTX) in Q2 2024, closing a stake of 116 shares — an estimated $160 sold.

Wells Fargo first reported a position in CNTX in Q4 2021 and held it in 10 quarters. The position peaked at $171 in Q2 2023. 34 funds tracked by Wall St. Rank hold CNTX as of Q2 2024.

Wells Fargo reported no remaining Context Therapeutics position as of Q2 2024 after selling out during the quarter.
Wells Fargo sold 116 Context Therapeutics shares in Q2 2024, an estimated $160.
Wells Fargo first reported a position in Context Therapeutics in Q4 2021 and held it in 10 quarters.
Wells Fargo's Context Therapeutics position peaked at $171 in Q2 2023.
34 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2024.

Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.